Bone Metastases in Breast Cancer: — PET-CT or Bone Scan?

Neither test is better in all cases — each finds different kinds of metastases. PET-CT is more sensitive for metabolically active, lytic lesions. It also provides a whole-body picture that includes soft tissue and lymph nodes. Bone scans are more sensitive for sclerotic lesions, which are common in breast cancer and can be completely PET-negative even when present. NCCN and ESMO guidance supports either test for bone assessment in metastatic breast cancer, with the choice driven by what your oncologist needs to assess.

Because bone scans find things PET-CT can miss — specifically sclerotic metastases, where bone becomes denser rather than being destroyed. These lesions have low glucose activity. They often do not appear on PET-CT at all. In breast cancer, sclerotic or mixed lesions are particularly common. A bone scan is also considerably more affordable and more widely available in India. Both tests have a defined and complementary role.

A bone scan is considerably less expensive than PET-CT in India. Both are indicative costs that vary by centre and city. Cost alone should not drive the decision — a cheaper test that misses what your oncologist needs to see is not a saving. Ask your team which investigation answers the clinical question they are working with, and what the out-of-pocket cost will be at your centre.

Both results may be correct — they are detecting different biological signals. A bone scan detects bone remodelling activity; a PET-CT detects glucose consumption. A sclerotic lesion, a healing lesion, or an area affected by prior treatment can be active on a bone scan and silent on PET. Your oncologist will interpret both results in the context of your symptoms, treatment history, and changes from previous imaging. Ask them what the discordant result means in your specific situation.

Not routinely. NCCN, ESMO, and ASCO guidance does not recommend PET-CT for staging early breast cancer — stage I or stage II disease without clinical signs of spread. In early-stage disease, the rate of misleading results is higher. Findings at that stage rarely change management. PET-CT is used when disease is locally advanced, when spread is suspected on clinical grounds, or when a whole-body assessment is needed before a specific treatment.

There is no fixed interval that applies to every patient. Repeat bone scans are generally ordered when there is a new bone symptom, when a treatment change is being considered, or when your oncologist needs to assess response. Routine surveillance imaging in the absence of symptoms or a specific clinical question is not recommended by NCCN or ESMO for metastatic breast cancer. Your team will discuss the timing that makes sense for your situation.